• Aldeyra Therapeutics President and CEO Todd C. Brady bought 250,000 common shares in open-market transactions.
• The purchases were priced at a weighted average of $1.67 per share.
• Brady’s direct holding rose to 1,721,298 shares following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-259637), on June 05, 2026, and is solely responsible for the information contained therein.